SNShinsuke Nakazawa

Shinsuke Nakazawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shinsuke Nakazawa has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A case of telogen effluvium followed by alopecia areata after SARS‐CoV‐2 infection

    by Reiko Kageyama, Taisuke Ito, Shinsuke Nakazawa, Takatoshi Shimauchi, Toshiharu Fujiyama, Tetsuya Honda


  • Decreased serum level of suprabasin in patients with nickel allergy

    by Shinsuke Nakazawa, Pawit Phadungsakswasdi, Hazuki Kageyama, Kensuke Fukuchi, Takatoshi Shimauchi, Toshiharu Fujiyama, Taisuke Ito, Tetsuya Honda


  • Open Access

    Plantar pustules in a psoriasis patient during the guselkumab therapy

    by Shinsuke Nakazawa, Tetsuya Honda

    The psoriasis vulgaris patient was treated with guselkumab. Two weeks after the first injection, multiple pustules developed on the bilateral plantar.

  • Open Access

    Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata

    by Reiko Kageyama, Taisuke Ito, Shiho Hanai, Naomi Morishita, Shinsuke Nakazawa, Toshiharu Fujiyama, Tetsuya Honda, Yoshiki Tokura

    Alopecia areata (AA) is regarded as a tissue-specific and cell-mediated autoimmune disorder. Regarding the cytokine balance, AA has been considered a type 1 inflammatory disease. On the other hand, AA often complicates atopic dermatitis (AD) and AD is regarded as type 2 inflammatory disease. However, the immunological aspects of AA in relation to AD are still poorly understood. Therefore, we aim to clarify the immunological properties of AD-associated AA. In this study, we performed comparative analysis of the expression of intracytoplasmic cytokines (IFN-γ, IL-4, and IL-13), chemokine receptors (CXCR3 and CCR4) in peripheral blood which were taken from healthy controls, non-atopic AA patients, AA patients with extrinsic AD, and AA patients with intrinsic AD by flowcytometric analysis. We also compared the scalp skin samples taken from AA patients with extrinsic AD before and after treatment with dupilumab. In non-atopic AA patients, the ratios of CD4+IFN-γ+ cells to CD4+IL-4+ cells and CD4+IFN-γ+ cells to CD4+IL-13+ cells were higher than those in AA patients with extrinsic AD. Meanwhile, the ratio of CD8+IFN-γ+ cells to CD8+IL-13+ cells was significantly higher in the non-atopic AA than in the healthy controls. In AA patients with extrinsic AD, the skin AA lesion showed dense infiltration of not only CXCR3+ cells but also CCR4+ cells around hair bulb before dupilumab treatment. However, after the treatment, the number of CXCR3+ cells had no remarkable change while the number of CCR4+ cells significantly decreased. These results indicate that the immunological condition of AA may be different between atopic and non-atopic patients and between extrinsic and intrinsic AD patients. Our study provides an important notion that type 2 immunity may participate in the development of AA in extrinsic AD patients. It may be considered that the immunological state of non-atopic AA is different from that of atopic AA.


  • Open Access

    Suprabasin-null mice retain skin barrier function and show high contact hypersensitivity to nickel upon oral nickel loading

    by Shinsuke Nakazawa, Takatoshi Shimauchi, Atsuko Funakoshi, Masahiro Aoshima, Pawit Phadungsaksawasdi, Jun-Ichi Sakabe, Sanki Asakawa, Noriyasu Hirasawa, Taisuke Ito, Yoshiki Tokura

    Suprabasin (SBSN) is expressed not only in epidermis but also in epithelial cells of the upper digestive tract where metals such as nickel are absorbed. We have recently shown that SBSN level is decreased in the stratum corneum and serum of atopic dermatitis (AD) patients, especially in intrinsic AD, which is characterized by metal allergy. By using SBSN-null (Sbsn–/–) mice, this study was conducted to investigate the outcome of SBSN deficiency in relation to AD. Sbsn–/– mice exhibited skin barrier dysfunction on embryonic day 16.5, but after birth, their barrier function was not perturbed despite the presence of ultrastructural changes in stratum corneum and keratohyalin granules. Sbsn–/– mice showed a comparable ovalbumin-specific skin immune response to wild type (WT) mice and rather lower contact hypersensitivity (CHS) responses to haptens than did WT mice. The blood nickel level after oral feeding of nickel was significantly higher in Sbsn–/– mice than in WT mice, and CHS to nickel was elevated in Sbsn–/– mice under nickel-loading condition. Our study suggests that the completely SBSN deficient mice retain normal barrier function, but harbor abnormal upper digestive tract epithelium that promotes nickel absorption and high CHS to nickel, sharing the features of intrinsic AD.


  • Open Access

    Protective role of Galectin‐7 for skin barrier impairment in atopic dermatitis

    by Takatsune Umayahara, Takatoshi Shimauchi, Manami Iwasaki, Jun‐Ichi Sakabe, Masahiro Aoshima, Shinsuke Nakazawa, Tsuyoshi Yatagai, Hayato Yamaguchi, Pawit Phadungsaksawasdi, Kazuo Kurihara, et al.

    Background: Atopic dermatitis (AD) patients have a barrier disorder in association with Th2 dominant skin inflammation. Galectin‐7 (Gal‐7), a soluble unglycosylated lectin, is highly expressed in the stratum corneum of AD patients. However, the biological significance of increased Gal‐7 expression in AD skin lesions remains unclear.Objective: We aimed to investigate the production mechanism and functional role of Gal‐7 in AD patients and IL‐4/IL‐13–stimulated epidermal keratinocytes.Methods: We assessed the Gal‐7 expression levels in skin lesions and sera from AD patients. Gal‐7 levels were also measured in monolayered normal human epidermal keratinocytes (NHEKs) and 3‐dimensional (3D)–reconstructed epidermis in the presence or absence of IL‐4/IL‐13 with or without Stat3, Stat6 or Gal‐7 gene silencing.Results: Gal‐7 was highly expressed in the stratum corneum or intercellular space of AD lesional epidermis as assessed by the stratum corneum proteome analysis and immunohistochemistry. A positive correlation was noted between serum Gal‐7 level and transepidermal water loss in patients with AD. These clinical findings were corroborated by our in vitro data, which showed that IL‐4/IL‐13 facilitated the extracellular release of endogenous Gal‐7 in both monolayered NHEKs and 3D‐reconstructed epidermis. This machinery was caused by IL‐4/IL‐13–induced cell damage and inhibited by knockdown of Stat6 but not Stat3 in NHEKs. Moreover, we performed Gal‐7 knockdown experiment on 3D‐reconstructed epidermis and the result suggested that endogenous Gal‐7 serves as a protector from IL‐4/IL‐13–induced disruption of cell‐to‐cell adhesion and/or cell‐to‐extracellular matrix adhesion.Conclusion and Clinical Relevance: Our study unveils the characteristic of Gal‐7 and its possible role as an alarmin that reflects the IL‐4/IL‐13–induced skin barrier impairment in AD.


  • Open Access

    Inflammatory granuloma mimicking lacrimal sac abscess

    by Mizuho Tajima, Shinsuke Nakazawa, Taisuke Ito, Yoshiki Tokura

    A 58‐year‐old Japanese woman presented with a 3‐month history of a red nodule on the lower palpebral region. She had a telangiectatic, hard nodule on her right medial canthus without any discharge of pustules.

  • Congenital nail clubbing

    by Shinsuke Nakazawa, Hironori Niizeki, Kazuhiko Nakabayashi, Keiji Tanese, Yoshiki Tokura

  • Open Access

    Dyshidrosiform palmoplantar pemphigoid with low‐titer autoantibodies against BP180 NC16A

    by Shinsuke Nakazawa, Kentaro Izumi, Wataru Nishie, Hiroshi Shimizu, Yoshiki Tokura

    Dyshidrosiform pemphigoid (DP) is a variant of bullous pemphigoid, presenting with a bullous or vesicular eruption localized on the soles and palms, and thus, DP has clinical resemblance with dyshidrosiform dermatitis. Here, we report a case of DP with literature review, focusing on the titer of antibodies directing the NC16A domain and other regions on BP180. Our case had a low titer of anti‐BP180 NC16A antibodies, and our survey of literature disclosed that 10 of 20 cases of DP had low titers (index: <150, or <87.5 U/mL) of anti‐BP180 NC16A antibodies. It is an issue whether DP is caused merely by a low titer of anti‐BP180 NC16A antibodies or by BP‐autoantibodies targeting other regions of BP180. We therefore examined our case with full‐length BP180 ELISA and found the absence of such antibodies. Our study suggests that DP is associated with low‐titer anti‐NC16A antibodies but not with the presence of antibodies against other parts of BP180.

  • Complete type of pachydermoperiostosis with a novel mutation c.510G>A of the SLCO2A1 gene

    by Shinsuke Nakazawa, Tatsuyoshi Mori, Hironori Niizeki, Kazuhiko Nakabayashi, Yoshiki Tokura